266P - Is the overall survival after hormone therapy for hormone-receptor-positive, HER2-negative metastatic breast cancer still better than for triple-ne...

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Breast Cancer, Metastatic
Presenter Junichiro Watanabe
Citation Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365
Authors J. Watanabe1, T. Hayashi2, Y. Tadokoro2, S. Nishimura2, K. Takahashi2
  • 1Breast Oncology, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 2Breast Surgery, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP

Abstract

Background

Hormone-receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (MBC), i.e. luminal-type MBC, is known to have a better prognosis than triple-negative MBC (TNMBC). However, if HR + HER2-MBC patients (pts) are diagnosed to be resistant to hormone therapy (HTx), they must undergo chemotherapy (CTx), just like TNMBC pts. To our knowledge, however, the overall survival (OS) after HTx (the OS derived from CTx) has not been well discussed.

Methods

We herein reviewed our medical records from 2002 to the present to assess the OS beyond HTx and identify the prognostic factors in HR + HER2-MBC pts. Statistical analyses were performed using the Kaplan-Meyer method and a multivariate COX regression analysis.

Results

We identified 344 HR + HER2-MBC pts from our medical records, and 286 (207 recurrent [rBC], 79 advanced [aBC]) underwent CTx. Among those 286 pts, 239 (83.6%) received at least 1 or more HTx sessions prior to CTx, while the other 47 (16.4%) received CTx as their initial systemic therapy. We also extracted 95 (69 rBC, 26 aBC) TNMBC pts from the records as a control group. The median OS for the 286 pts from the diagnosis of MBC was 1395.0 days (95% confidence interval [CI] 500.0-3942.0), which was superior to that of TNMBC pts (777.0 days, 95%CI 238.0-1784.0, p 

Conclusions

Our single-institution retrospective analysis with some limitations found that the OS after HTx in recurrent HR + HER2-BC pts was almost identical to that of recurrent TNBC pts.

Clinical trial identification

This is not a prospective trial, so, it has no trial number.

Legal entity responsible for the study

Junichiro Watanabe

Funding

None

Disclosure

All authors have declared no conflicts of interest.